ASH 2023
Fred Hutchinson Cancer Center’s latest findings on blood and marrow transplantation, cell therapies, precision medicine and more will be featured at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH).
This year's annual meeting will be held at the San Diego Convention Center in San Diego, California and virtually for those who cannot attend in person.
The ASH meeting provides an invaluable educational experience and the latest on the hottest topics in hematology. Attendees include top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.
The meeting features the annual E. Donnall Thomas Lecture, named for the Fred Hutch physician-scientist who was awarded the Nobel Prize in physiology or medicine for his development of bone marrow transplantation. This year, the lecture will be held on Monday, December 11, 2023.
Visit the Fred Hutch booth #3337.
Featured Sessions
Scientific Workshop
Diagnostic Testing in Classical Hematologic Disorders
Presenter: Sandhya R Panch, MD
Session: Advanced Testing Techniques in Autoimmune Hemolytic Anemia/Role of Molecular Testing in Transfusion Medicine
Friday, Dec. 8, 2:05-3:20 pm
San Diego Convention Center, Room 28 A-D
Scientific Workshop
New Treatments for CMV Reactivation after Hematopoietic Stem Cell Transplant
Presenter: Michael Boeckh, MD, PhD
Session: The Landscape of Viral Reactivation After Transplantation
Friday, Dec. 8, 3:33-4:13 pm
San Diego Convention Center, Room 8
Scientific Education
Dual Targeted Regimens for the Front-line Treatment of CLL
Presenter: Chaitra Ujjani
Session: How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
Saturday, Dec. 9, 2:00-3:15 pm
San Diego Convention Center, Ballroom 20CD
Scientific Symposia
Alternate Immune Effector Cells
Presenter: Marie Bleakley, MD, PhD, MMSC
Presentation: Advances in TCR Based Therapeutics for Hematologic Malignancies
Saturday, Dec. 9, 3 pm
San Diego Convention Center, Room 6DE
Scientific Symposia
The Role of the Microbiota on Hemopoiesis and Immune Reconstitution after Therapy
Presenter: Kate Markey, MD
Session: The Impact of the Microbiota on Immunotherapy of Hematological Malignancies
Sunday, Dec. 10, 9:30-10:45 am
San Diego Convention Center, Room 25
Meet the Blood Advances Editors
Panelist: Geoffrey Hill, MD, FACP, FRCPA
Monday, Dec. 11, 2023, 10-11 am
San Diego Convention Center, Hall A
Symposia
Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular
Moderator: Roland B. Walter, MD, PhD, MS
Presentation: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML
Monday, Dec. 11, 2:45-4:15 pm
Marriot Marquis San Diego Marina, Grand Ballroom AB
Symposia
Health Services and Quality Improvement - Lymphoid Malignancies Program
Presenter: Andrew J. Cowan, MD
Presentation: Health Services and Quality Improvement Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias
Monday, Dec. 11, 2:45-4:15 pm
Marriott Marquis San Diego Marina, Grand Ballroom 2-4
Symposia
Cellular Immunotherapies: Early Phase and Investigational Therapies Program
Presenter: Damian J. Green, MD
Presentation: Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas
Monday, Dec. 11, 4:30-6 pm
San Diego Convention Center, Room 6A
Highlights of Fred Hutch Presentations at ASH
Saturday, December 9 | Sunday, December 10 | Monday, December 11
Rabbit Antithymocyte (rATG) Exposure and Outcomes after Hematopoietic Cell Transplantation: A Real World Experience from BMT CTN 1202Description: In this moderated session, researchers will share results of efforts in treating multiple myeloma.
Abstract No. 111
Presenter: Madhavi Lakkaraja, MD, MPH
Saturday, Dec. 9, 10 am
Location: San Diego Convention Center, Room 11
BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model
Abstract No. 53
Presenter: Damian Green, MD
Saturday, Dec. 9, 10:30 am
Location: Manchester Grand Hyatt, Grand Hall D
Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826
Abstract No. 181
Presenter: Hongli Li, MS
Saturday, Dec. 9, 2 pm
Location: Manchester Grand Hyatt, Grand Hall D
MMF Is Associated with Worse OS in CMV Seropositive AML Patients Undergoing MUD HCT with Calcineurin-Inhibitor-Based Gvhd Prophylaxis
Abstract No. 236
Presenter: Rotesh S. Mehta, MD, MPH
Saturday, Dec. 9, 2:15 pm
Location: San Diego Convention Center, Room 7
Out-of-Pocket Costs and Financial Hardship Among Participants of the BMT CTN 1102 Study
Abstract No. 262
Presenter: Christopher T. Su, MD, MPH
Saturday, Dec. 9, 2:45 pm
Location: San Diego Convention Center, Hall A
Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Abstract No. 269
Presenter: Mazyar Shadman, MD MPH
Saturday, Dec. 9, 3 pm
Location: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22
CLEC2A Is a Novel AML-Restricted Immunotherapeutic Target Enriched in KMT2A-Rearranged Acute Myeloid Leukemia
Abstract No. 290
Presenter: Danielle C. Kirkey, MD
Saturday, Dec. 9, 4:15 pm
Location: San Diego Convention Center, Room 6CF
Microbiota-Specific T Cells Contribute to Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
Abstract No. 345
Presenter: Albert C. Yeh, MD
Saturday, Dec. 9, 4:30 pm
Location: San Diego Convention Center, Room 7
Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004
Abstract No. 330
Presenter: David G. Maloney, MD, PhD
Saturday, Dec. 9, 5:15 pm
Location: Manchester Grand Hyatt San Diego, Grand Hall D
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET® BMS-986357 (CC-96191)
Abstract No. 1431
Presenter: Magaret C. Lunn
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
LAMP5 Is an AML-Restricted Immunotherapeutic Target Enriched in High-Risk Acute Myeloid Leukemia
Abstract No. 1585
Presenter: Danielle C. Kirkey, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas
Abstract No. 1708
Presenter: Christina Poh, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders
Abstract No. 1781
Presenter: MGeorge S. Laszlo, PhD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Successful Treatment-Free Remission in Low- and Middle-Income Countries
Abstract No. 1808
Presenter: Jerald Radich, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions
Abstract No. 1976
Presenter: Andrew J. Portuguese, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Trogocytosis May Attenuate the Efficacy of Anti-BCMA CAR T Cells Administered in Combination with γ-Secretase Inhibitor
Abstract No. 2083
Presenter: Pinar Ataca Atilla, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial
Abstract No. 2102
Presenter: Mazyar Shadman, MD, MPH
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel
Abstract No. 2126
Presenter: Aya Albitar, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
Abstract No. 2129
Presenter: Christina Poh, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting
Abstract No. 2131
Presenter: Andrew J. Portuguese, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
Abstract No. 2137
Presenter: Jordan Gauthier, MD, MSc
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy
Abstract No. 2143
Presenter: Emily C. Liang, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma
Abstract No. 2224
Presenter: Maryam Ebadi, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
CD90-Targeted Cocal-Pseudotyped Lentivirus As a Robust Platform for Human HSC Gene Therapy
Abstract No. 2254
Presenter: Justin Thomas, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Shotgun Sequencing of Multi-Site Oral and Colonic Microbiota in Patients with AML: Site-Specific Patterns and Microbiota Decompartmentalization
Abstract No. 2273
Presenter: Armin Rashidi, MD, PhD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Rapid Clinical Mutation Screening for AML Using the Genexus Platform
Abstract No. 2288
Presenter: Jerald Radich, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL
Abstract No. 2386
Presenter: Rahul Banerjee, MD, FACP
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Impaired Cognitive Function in Immune-TTP Is Better Predicted By Serum Thrombomodulin Than ADAMTS13 Activity: Results of a Longitudinal Multicenter Pilot Study
Abstract No. 2386
Presenter: Aaron Boothby, MD
Saturday, Dec. 9, 5:30-7:30 pm
Location: San Diego Convention Center, Halls G-H
Efficient and Stable Makassar Base Editing in Nonhuman Primates
Abstract No. 484
Presenter: Stefan Radtke, PhD
Sunday, Dec. 10, 10:15 am
Location: San Diego Convention Center, Ballroom 20CD
Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study
Abstract No. 522
Presenter: Noam E. Kopar, MD
Sunday, Dec. 10, 1:15 pm
Location: Manchester Grand Hyatt San Diego, Grand Hall B
Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy
Abstract No. 3495
Presenter: Jennifer J. Huang, MD, PhD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis
Abstract No. 3497
Presenter: Mayzar Shadman, MD, MPH
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy
Abstract No. 3509
Presenter: Rahul Banerjee, MD, FACP
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Allogeneic Hematopoietic Cell Transplantation in the 7th Decade of Life and Beyond
Abstract No. 3608
Presenter: Mary-Elizabeth M. Percival, MD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Zinc Status Affects T Cell Reconstitution in Patients Receiving Naïve T Cell Depleted Allogeneic HSCT
Abstract No. 3562
Presenter: Lorenzo Iovino, MD, PhD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Care Patterns and Barriers to Outpatient Care for Adults with Acute Myeloid Leukemia (AML) Following Intensive Chemotherapy at National Comprehensive Cancer Network (NCCN) Institutions
Abstract No. 3722
Presenter: Anna Halpern, MD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Testing the Limits of Endogenous Thymic Regeneration after HCT Conditioning
Abstract No. 33562
Presenter: Dante Dennis Acenas II
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Hematopoietic Stem Cell Transplantation (HCT) Conditioning Leads to NK Cell Cytotoxicity Limiting Endogenous Thymus Regeneration
Abstract No. 461
Presenter: David Granadier, BS
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Abstract No. 3809
Presenter: Megan Othus, PhD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Elevated Metabolite Secretion Facilitates a Treg-Mediated Immunosuppressive Microenvironment in the Solid Tumor
Abstract No. 3458
Presenter: Sinéad Kinsella, MSc, PhD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Identifying a Relapse Signature in CBFB-MYH11 Acute Myeloid Leukemia
Abstract No. 2955
Presenter: Jack H Peplinski, BS
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Evaluation of ECOG Performance Status at Diagnosis and Relapse in Patients with Acute Myeloid Leukemia
Abstract No. 2844
Presenter: Carole Shaw
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Prognostic Value of Copy Number Aberrations and Copy Neutral Loss of Heterozygosity in Acute Myeloid Leukemia
Abstract No. 2945
Presenter: Suravi Raychaudhuri, MD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies
Abstract No. 3777
Presenter: Andrew J. Cowan, MD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Heterogeneity of TP53 Mutations in Mantle Cell Lymphoma- Challenges in Risk Stratification and Subclassification
Abstract No. 3047
Presenter: Carrie I Ho, MD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid Neoplasms
Abstract No. 2897
Presenter: Suravi Raychaudhuri, MD
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Binary Gender Differences in Quality of Life and Social Supports Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry
Abstract No. 2592
Presenter: Terry Gernsheimer
Sunday, Dec. 10, 6-8 pm
Location: San Diego Convention Center, Halls G-H
Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission
Abstract No. 781
Presenter: Mazyar Shadman, MD, MPH
Monday, Dec. 11, 10:30 am
Location: San Diego Convention Center, Hall A
MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition StudyClinically Relevant Abstract
Abstract No. 1033
Presenter: Kate Markey, MD, BS, MClin Res, PhD, FRACP
Monday, Dec. 11, 4:30 pm
Location: San Diego Convention Center, Room 6DE
Combined Effect of Unrelated Donor Age and HLA Peptide-Binding Motifs (PBM) Match Status on HCT OutcomesClinically Relevant Abstract
Abstract No. 1045
Presenter: Rotesh S. Mehta, MD
Monday, Dec. 11, 4:30 pm
Location: San Diego Convention Center, Ballroom 20CD
Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies
Abstract No. 1040
Presenter: Filippo Milano, MD, PhD
Monday, Dec. 11, 4:45 pm
Location: San Diego Convention Center, Ballroom 20AB
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211
Abstract No. 1066
Presenter: Rahul Banerjee, MD, FACP
Monday, Dec. 11, 5:15 pm
Location: Marriott Grand Ballroom 2-4
Association between Low Bone Mineral Density and Pain in a Prospective Cohort of Adults with Sickle Cell Disease: Preliminary Results from the SCD Bone Pain Study
Abstract No. 3880
Presenter: Qian Wu, PhD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Integrative Genome and Transcriptome Sequencing Analysis Indicates Genetic and Epigenetic Dysregulation in DS-AML
Abstract No. 4306
Presenter: Rhonda E. Ries, MA
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML
Abstract No. 4295
Presenter: Soheil Meshinchi, MD, PhD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
DNMT3A Mutants Are Enriched in NPMc+ AML and Associated with Adverse Outcome in Childhood AML
Abstract No. 4306
Presenter: Rhonda E. Ries, MA
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
Abstract No. 4308
Presenter: Naveed Ali, MBBS
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML
Abstract No. 4315
Presenter: Naveed Ali, MBBS
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Identification of a Relapse Signature in t(8;21) Pediatric AML
Abstract No. 4318
Presenter: Logan K. Wallace
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Identification of a Novel AML Patient Subset Sensitive to Venetoclax Using Matched Proteomics and Diverse Ex Vivo Models
Abstract No. 4338
Presenter: Derek Stirewalt, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome
Abstract No. 4397
Presenter: Ryan Lynch, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD
Abstract No. 4429
Presenter: Ryan Lynch, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
A Phase 1 Study of Subcutaneous Rituximab Hyaluronidase Combined with Local Standard-of-Care Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda
Abstract No. 4467
Presenter: Henry Ddugnu, MD, PhD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of Double-Refractory Status in Patients with CLL/SLL
Abstract No. 4650
Presenter: Laura Samples, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
Abstract No. 4655
Presenter: Mazyar Shadman, MD, MPH
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors
Abstract No. 4656
Presenter: Laura Samples, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model
Abstract No. 4821
Presenter: Danielle C. Kirkey, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Multispecific Hybrid T Cell Receptors for Sensitive Targeting of Cancer
Abstract No. 4822
Presenter: Sylvain Simon, PhD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Leukemia Blasts Induce NK-like Dysfunction in AML-Specific T Cells
Abstract No. 4849
Presenter: Francesco Mazziotta, MD, MPH
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Dynamics of Fecal Antibiotic-Resistance Genes after Fecal Microbiota Transplantation in Allogeneic Hematopoietic Cell Transplant Recipients and AML Patients: Results from a Randomized Placebo-Controlled Trial
Abstract No. 4936
Presenter: Armin Rashidi, MD, PhD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Lymphocyte Reconstitution after Naïve T Cell-Depleted Hematopoietic Cell Transplantation
Abstract No. 4937
Presenter: Melinda Ann Biernacki, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Neoplasms
Abstract No. 4956
Presenter: Emily Merkel, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians
Abstract No. 5073
Presenter: Rahul Banerjee, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma – a National All-Payer Claims Database Study
Abstract No. 5087
Presenter: Rahul Banerjee, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL
Abstract No. 5149
Presenter: Chaitra S. Ujjani, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals with Relapsed/Refractory Multiple Myeloma
Abstract No. 5191
Presenter: Rahul Banerjee, MD
Monday, Dec. 11, 6-8 pm
Location: San Diego Convention Center, Hall G-H
Contact Our Media Relations Team
For more information or to arrange an interview, please email or call our media relations team.